Drug resistance profiles among HIV-1-infected children experiencing delayed switch and 12-month efficacy after using second-line antiretroviral therapy: An observational cohort study in rural China

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 1, 2011, Pages 47-53

  Zhao, Yan ^a   Mu, Weiwei ^a   Harwell, Joseph ^b   Zhou, Haiwei ^c   Sun, Xin ^a   Cheng, Yuewu ^d   Li, Chunming ^a   Zhang, Fujie ^a,c  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b BROWN UNIVERSITY   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d Shang Cai Country Center for Disease Control and Prevention   (China)

Author keywords

Children; Drug resistance; HIV; Secondline antiretroviral therapy; Virologic failure

Indexed keywords

ABACAVIR; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CHINA; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; VIRUS LOAD; ADOLESCENT; DRUG EFFECT; DRUG SUBSTITUTION; GENETICS; GENOTYPE; RURAL POPULATION; VIROLOGY;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHINA; COHORT STUDIES; DRUG RESISTANCE, VIRAL; DRUG SUBSTITUTION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; RURAL POPULATION;

EID: 80155198760     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318229f2a2     Document Type: Article

References (32)

1. UNAIDS report on the global AIDS epidemic 2010. Available at: http://www.unaids.org/documents/20101123-GlobalReport-Chap2-em.pdf. Accessed November 23, 2010.
2. More than four million HIV-positive people now receiving lifesaving treatment. Global Health Observatory (GHO). Available at: http://www.who.int/ gho/mdg/diseases/hiv/situation-trends-art/en/index.html. Accessed September 30, 2010.
3. Brady MT, Oleske JM, Williams PL, et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr. 2010;53:86-94.
4. Nakhmanina NY, van den Anker JN. Treating an HIV-infected paediatric patient: an easy task? Antivir Ther. 2010;15:293-296.
5. Burger D, Ewings F, Kabamba D, et al. Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets. Ther Drug Monit. 2010;32:369-372.
6. Puthanakit T, van der Lugt J, Bunupuradah T, et al. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. J Antimicrob Chemother. 2009;64:1080-1086.
7. Agwu A, Lindsey JC, Ferguson K, et al. Analyses of HIV-1 drugresistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy. AIDS Patient Care STDS. 2008;22:545.
8. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46:187-193. (Pubitemid 47482614)
9. Zhao Y, Sun X, He Y, et al. Progress of the National Pediatric Free Antiretroviral Therapy program in China. AIDS Care. 2010;26:1-7.
10. Zhang FJ, Haberer J, Wei H, et al. Drug resistance in the Chinese National Pediatric Highly Active Antiretroviral Therapy Cohort: implications for paediatric treatment in the developing world. Int J STD AIDS. 2009;20:406-409.
11. Li JY, Li HP, Li L, et al. Prevalence and evolution of drug resistance HIV-1 variants in Henan, China. Cell Res. 2005;15:843-849. (Pubitemid 41826249)
12. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233-2244.
13. Emmett SD, Coleen K, Cunningham, et al. Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study. J Acquir Immune Defic Syndr. 2010;54:368-375.
14. Davies MA, Moultrie H, Eley B, et al. Virologic failure and second-line antiretroviral therapy in children in South Africa-The IeDEA Southern Africa Collaboration. J Acquir Immune Defic Syndr. 2011;56:270-278.
15. Skovdal M, Campbell C, Madanhire C, et al. Challenge faced by elderly guardians in sustaining the adherence to antiretroviral therapy in HIV infected children in Zimbabwe. AIDS Care. 2011;10:1-8.
16. Zhang FJ, Haberer JE, Zhao Y, et al. Chinese pediatric highly active antiretroviral therapy observational cohort-a 1-year analysis of clinical, immunologic, and virologic outcomes. J Acquir Immune Defic Syndr. 2007;46:594-598. (Pubitemid 350191053)
17. Jittamala P, Puthanakit T, Chaiinseeard S, et al. Predictors of virologic failure and genotypic resistance mutation patterns in Thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis. 2009;28:826-830.
18. Janssens B, Raleigh B, Soeung S, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics. 2007;120:e1134-e1140. (Pubitemid 350085507)
19. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis. 2005;41:100-107. (Pubitemid 40863751)
20. Puthanakit T, Jourdain G, Hongsiriwon S, et al. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. HIV Med. 2010;11:565-572.
21. Ruel TD, Kamya MR, Pelin Li, et al. Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr. 2011;56:44-50.
22. Hurwitz SJ, Asif G, Kivel NM, et al. Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model. Antimicrob Agents Chemother. 2008;52:4241-4250.
23. Anderson PL, Rower JE. Zidovudine and lamivudine for HIV infection. Clin Med Rev Ther. 2010;2:a2004.
24. Sohn AH, Nuttall JJC, Zhang FJ. Sequencing of antiretroviral therapy in children in low-and middle-income countries. Current Opinion in HIVand AIDS. 2010;5:54-60.
25. Bunupuradah T, Suntarattiwong P, Li A, et al. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors. Int Soc Infect Dis. 2010;14:e311-e316.
26. Bunupuradah T, van der Lugt J, Kosalaraksa P, et al. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. Antivir Ther. 2009;14:241-248.
27. Swindells S, Di Rienza AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA. 2006;296:806-814. (Pubitemid 44223104)
28. Llibre JM. First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients-making a good thing better. AIDS Rev. 2009;11:215-222.
29. von Hentig N. Lopinavir/ritonavir: appraisal of its use in HIV therapy. Drugs Today (Barc). 2007;43:221-247. (Pubitemid 47177209)
30. Bunupuradah T, Kosalaraksa P, Puthanakit T, et al. Monoboosted lopinavir/ritonavir as simplified second-line maintenance therapy in virologically suppressed children. AIDS. 2011;25:315-323.
31. Bartlett JA, Aga E, Ribaudo H, et al. A pilot study of LPV/r monotherapy following virologic failure of first line NNRTI-containing regimens in resource-limited settings: week 24 primary analysis of ACTG5230 [abstract 583]. Presented at: XVIII Conference on Retroviruses and Opportunistic Infections; March 2, 2011; Boston, MA.
32. Tubiana R, Mandelbrot L, Delmas S, et al. LPV/r monotherapy during pregnancy for PMTCT of HIV-1: the PRIMEVA/ANRS 135 randomized trial, pregnancy outcomes [abstract 125lb]. Presented at: XVIII Conference on Retroviruses and Opportunistic Infections; March 2, 2011; Boston, MA.